1.9 B Material Changes: There must not be any undisclosed Material Changes in respect of the Issuer at the time the Issuer reserves the proposed offering price (or Conversion Price). The Issuer must also disclose any Material Changes in respect of the Issuer which occur during the course of the Private Placement process.
Any such Material Changes may affect the minimum acceptable offering price or Conversion Price permitted by the Exchange.
Answers....we want answers David. Speak please. Give us an update to the lab work and remaining experiments. Why does the Government Of Canada website say funding expected this business year for Vaxil Bio for work on Covid 19 clinical trials?
Wave 2 is here, so the media is pushing....Would an update to the shareholders that allowed your company to recently cash in the warrants to the tune of 1.4 million dollars be too much to ask?